Craig Webb joined the drug repurposing Stanford spin-off Numedii in July 2013 as Chief Scientific Officer. The firm combines big data, informatics and translational medicine expertise to identify new indications for existing drugs. Previously as one of the founding scientists at the Van Andel Research Institute in Michigan, Craig has spent the past 13 years building a translational research enterprise focused on the application of genomic technologies in medicine. In addition to establishing a successful basic science laboratory focused on deciphering the molecular mechanisms of tumor metastasis and drug resistance, his work also focused on the early development of precision medicine clinical trials using tumor molecular profiling. These efforts resulted in the formation of four companies in areas of bioinformatics, molecular diagnostics and clinical trial coordination (TransMed Systems, Intervention Insights, The Center for Molecular Medicine and ClinXus). Craig has a BSc in Biochemistry, a PhD in cell biology and has done post doctoral work in molecular oncology.